Get the Stockscreener App
4.95
7.14%
0.33
After Hours:
4.92
-0.03
-0.61%
Candel Therapeutics Inc stock is traded at $4.95, with a volume of 678.45K.
It is up +7.14% in the last 24 hours and down -11.61% over the past month.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
See More
Previous Close:
$4.62
Open:
$4.7
24h Volume:
678.45K
Relative Volume:
2.03
Market Cap:
$147.44M
Revenue:
$124.00K
Net Income/Loss:
$-49.99M
P/E Ratio:
-4.4595
EPS:
-1.11
Net Cash Flow:
$-31.03M
1W Performance:
+24.37%
1M Performance:
-11.61%
6M Performance:
-36.54%
1Y Performance:
+405.10%
1-Day Range:
$4.54
$5.02
1-Week Range:
$3.965
$5.57
52-Week Range:
$0.77
$14.30
Candel Therapeutics Inc Stock (CADL) Company Profile
Name
Candel Therapeutics Inc
Sector
Industry
Phone
617-916-5445
Address
117 KENDRICK STREET, NEEDHAM
Compare CADL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
4.95 | 147.44M | 124.00K | -49.99M | -31.03M | -1.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-22 | Initiated | H.C. Wainwright | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Aug-23-21 | Initiated | Credit Suisse | Outperform |
| Aug-23-21 | Initiated | Jefferies | Buy |
| Aug-23-21 | Initiated | UBS | Buy |
Candel Therapeutics Inc Stock (CADL) Latest News
Candel Therapeutics CEO: Putting patients first is the key to reframing cancer treatment - Proactive Investors USA
HC Wainwright Issues Pessimistic Estimate for CADL Earnings - MarketBeat
Analysts Issue Forecasts for CADL Q4 Earnings - Defense World
HC Wainwright Reaffirms Buy Rating for Candel Therapeutics (NASDAQ:CADL) - Defense World
What is HC Wainwright's Estimate for CADL Q4 Earnings? - MarketBeat
Candel Therapeutics Advances in Cancer Trials Amid Financial Challenges - TipRanks
Candel Therapeutics' (CADL) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Candel Therapeutics, Inc. (NASDAQ:CADL) Short Interest Update - MarketBeat
Candel Therapeutics Inc (CADL) Quarterly 10-Q Report - Quartzy
Candel Therapeutics CEO anticipates 'paradigm shift' in prostate cancer treatment as Q3 work wraps up - Proactive Investors USA
Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - The Manila Times
Candel Therapeutics Reports $10.6M Q3 Loss, Advances Key Cancer Drug Trials for Q4 2024 | CADL Stock News - StockTitan
Insiders Could Have Profited By Holding onto Candel Therapeutics Shares Despite 10% Drop - Simply Wall St
Candel Therapeutics’ CAN-3110 offers new hope for melanoma treatment – ICYMI - Proactive Investors USA
CADLCandel Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Candel Therapeutics CEO to present at Jefferies London healthcare conference - Proactive Investors UK
Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024 - GlobeNewswire
Candel Therapeutics (NASDAQ:CADL) Shares Up 2.5%Should You Buy? - MarketBeat
Candel Therapeutics presents preclinical data with CAN-3110 in Melanoma model at SITC annual Meeting - Proactive financial news
Candel Therapeutics to Present Preclinical Data at SITC - GlobeNewswire
Candel Therapeutics Inc Share PriceCADL, RNS News, Articles, Quotes, & Charts (NASDAQ:CADL) - Proactive Investors USA
Candel Therapeutics eyes new indication for CAN-3110 in melanoma following positive preclinical results - Proactive Investors UK
Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma - StockTitan
Nfi Group Inc. (NFI-T) QuotePress Release - The Globe and Mail
Candel Therapeutics: A Low-Price Oncolytic Virus Play Further Along Than You Think - Seeking Alpha
Candel Therapeutics Advances in Cancer Treatment Trials - Yahoo Finance
Candel Therapeutics Showcases Innovative Cancer Therapy - GlobeNewswire
Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC) - StockTitan
Candel Therapeutics Prices IPO At $8/Share - RTTNews
Where are the Opportunities in (CADL) - Stock Traders Daily
Candel Therapeutics Poised for Breakthrough in Cancer Therapies, Key Trials to Read Out by Year-End - Proactive Investors Australia
Candel Therapeutics Share PriceCADL, RNS News, Articles, Quotes, & Charts (NASDAQ:CADL) - Proactive Investors USA
(CADL) Trading Advice - Stock Traders Daily
Candel Therapeutics, Inc. (NASDAQ:CADL) Major Shareholder Estuardo Aguilar-Cordova Sells 15,000 Shares - MarketBeat
Candel therapeutics investor sells $243,834 in stock By Investing.com - Investing.com South Africa
Banxa Holdings Inc (BNXAF) QuotePress Release - The Globe and Mail
How To Trade (CADL) - Stock Traders Daily
Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting - The Manila Times
Candel Therapeutics to Present Preclinical Data on - GlobeNewswire
Candel therapeutics insider sells shares worth over $240k By Investing.com - Investing.com South Africa
Candel therapeutics insider sells shares worth over $240k - Investing.com India
Candel Therapeutics, Inc. (NASDAQ:CADL) Major Shareholder Estuardo Aguilar-Cordova Sells 1,800 Shares - MarketBeat
Citigroup Raises Cogent Biosciences (NASDAQ:COGT) Price Target to $15.00 - Defense World
Citi raises Cogent price target on bezuclastinib potential - Investing.com India
Deeper Dive: Understanding Cg Oncology Inc. (CGON) Through its Various Ratios - The Dwinnex
(CADL) Proactive Strategies - Stock Traders Daily
Gaining Ground: Cogent Biosciences Inc (COGT) Closes Lower at 10.65, Down -3.01 - The Dwinnex
Cg Oncology Inc. [CGON] Stock sold by Insider Song Hong Fang for $23.0 million - Knox Daily
Capricor Therapeutics Shares Rise in Premarket on Plans to File Application for Deramiocel - MarketWatch
Cintas Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Benzinga
Farallon Capital Management LLC Decreases Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Candel Therapeutics Inc Stock (CADL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Candel Therapeutics Inc Stock (CADL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Aguilar-Cordova Estuardo | 10% Owner |
Oct 11 '24 |
Sale |
6.05 |
15,000 |
90,750 |
944,873 |
| Aguilar-Cordova Estuardo | 10% Owner |
Oct 14 '24 |
Sale |
6.02 |
15,000 |
90,300 |
929,873 |
| Aguilar-Cordova Estuardo | 10% Owner |
Oct 15 '24 |
Sale |
6.03 |
10,412 |
62,784 |
919,461 |
| Aguilar-Cordova Estuardo | 10% Owner |
Oct 02 '24 |
Sale |
6.92 |
26,988 |
186,757 |
961,673 |
| Aguilar-Cordova Estuardo | 10% Owner |
Oct 03 '24 |
Sale |
6.85 |
1,800 |
12,330 |
959,873 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):